187 related articles for article (PubMed ID: 36847423)
1. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up.
Cunha RN; Saraiva L; Jesus D; Doria A; da Silva JP; Inês LS
Rheumatology (Oxford); 2023 Nov; 62(11):3627-3635. PubMed ID: 36847423
[TBL] [Abstract][Full Text] [Related]
2. Impact of low disease activity, remission, and complete remission on flares following tapering of corticosteroids and immunosuppressive therapy in patients with systemic lupus erythematous: a multinational cohort study.
Cho J; Shen L; Huq M; Kandane-Rathnayake R; Golder V; Louthrenoo W; Chen YH; Hamijoyo L; Luo SF; Wu YJ; Zamora L; Li Z; Sockalingam S; Katsumata Y; Harigai M; Hao Y; Zhang Z; Basnayake D; Chan M; Kikuchi J; Takeuchi T; Bae SC; Oon S; O'Neill S; Goldblatt F; Ng KPL; Law A; Tugnet N; Kumar S; Tee C; Tee M; Ohkubo N; Tanaka Y; Navarra SV; Lau CS; Hoi A; Morand EF; Nikpour M; Lateef A;
Lancet Rheumatol; 2023 Oct; 5(10):e584-e593. PubMed ID: 38251484
[TBL] [Abstract][Full Text] [Related]
3. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: a validation study.
Saraiva L; Cunha RN; Jesus D; Gatto M; Zen M; Iaccarino L; da Silva JAP; Doria A; Inês LS
Rheumatology (Oxford); 2024 Apr; 63(4):1123-1129. PubMed ID: 37458482
[TBL] [Abstract][Full Text] [Related]
4. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.
Petri MA; van Vollenhoven RF; Buyon J; Levy RA; Navarra SV; Cervera R; Zhong ZJ; Freimuth WW;
Arthritis Rheum; 2013 Aug; 65(8):2143-53. PubMed ID: 23754628
[TBL] [Abstract][Full Text] [Related]
5. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
[TBL] [Abstract][Full Text] [Related]
6. Identification of clinical predictors of flare in systemic lupus erythematosus patients: a 24-month prospective cohort study.
Inês L; Duarte C; Silva RS; Teixeira AS; Fonseca FP; da Silva JA
Rheumatology (Oxford); 2014 Jan; 53(1):85-9. PubMed ID: 24067885
[TBL] [Abstract][Full Text] [Related]
7. Predicting flares in patients with stable systemic lupus erythematosus.
Cho J; Lahiri M; Teoh LK; Dhanasekaran P; Cheung PP; Lateef A
Semin Arthritis Rheum; 2019 Aug; 49(1):91-97. PubMed ID: 30660381
[TBL] [Abstract][Full Text] [Related]
8. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index.
Thanou A; Chakravarty E; James JA; Merrill JT
Rheumatology (Oxford); 2014 Dec; 53(12):2175-81. PubMed ID: 24729400
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of disease flares in a Chinese lupus cohort with low-grade disease activity.
Sun F; Zhao L; Wang H; Zhang D; Chen J; Wang X; Li T; Ye S
Lupus Sci Med; 2022 May; 9(1):. PubMed ID: 35606018
[TBL] [Abstract][Full Text] [Related]
10. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
Abdelhady EI; Rabie M; Hassan RA
Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
[TBL] [Abstract][Full Text] [Related]
11. Clinical response trajectories and drug persistence in systemic lupus erythematosus patients on belimumab treatment: A real-life, multicentre observational study.
Nikoloudaki M; Nikolopoulos D; Koutsoviti S; Flouri I; Kapsala N; Repa A; Katsimbri P; Theotikos E; Pitsigavdaki S; Pateromichelaki K; Bertsias A; Elezoglou A; Sidiropoulos P; Fanouriakis A; Boumpas D; Bertsias G
Front Immunol; 2022; 13():1074044. PubMed ID: 36685524
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and predictors of flare after immunosuppressant discontinuation in patients with systemic lupus erythematosus in remission.
Zen M; Saccon F; Gatto M; Montesso G; Larosa M; Benvenuti F; Iaccarino L; Doria A
Rheumatology (Oxford); 2020 Jul; 59(7):1591-1598. PubMed ID: 31642908
[TBL] [Abstract][Full Text] [Related]
13. Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study.
Zen M; Bassi N; Nalotto L; Canova M; Bettio S; Gatto M; Ghirardello A; Iaccarino L; Punzi L; Doria A
Clin Exp Rheumatol; 2012; 30(6):856-63. PubMed ID: 22765883
[TBL] [Abstract][Full Text] [Related]
14. The chronic damage in systemic lupus erythematosus is driven by flares, glucocorticoids and antiphospholipid antibodies: results from a monocentric cohort.
Conti F; Ceccarelli F; Perricone C; Leccese I; Massaro L; Pacucci VA; Truglia S; Miranda F; Spinelli FR; Alessandri C; Valesini G
Lupus; 2016 Jun; 25(7):719-26. PubMed ID: 26821965
[TBL] [Abstract][Full Text] [Related]
15. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
Pawlak-Buś K; Schmidt W; Leszczyński P
Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
[TBL] [Abstract][Full Text] [Related]
16. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
[TBL] [Abstract][Full Text] [Related]
17. Steroid-free remission in lupus: myth or reality; an observational study from a tertiary referral centre.
Goswami RP; Sit H; Ghosh P; Sircar G; Ghosh A
Clin Rheumatol; 2019 Apr; 38(4):1089-1097. PubMed ID: 30523554
[TBL] [Abstract][Full Text] [Related]
18. Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study.
de Luca Montes RA; Huq M; Godfrey T; Oon S; Calderone A; Kandane-Rathnayake R; Louthrenoo W; Luo SF; Jan Wu YJ; Golder V; Lateef A; Navarra SV; Zamora L; Hamijoyo L; Sockalingam S; An Y; Li Z; Katsumata Y; Harigai M; Chan M; Goldblatt F; O'Neill S; Lau CS; Cho J; Hoi A; Karyekar CS; Morand EF; Nikpour M
Adv Rheumatol; 2024 May; 64(1):38. PubMed ID: 38720354
[TBL] [Abstract][Full Text] [Related]
19. Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting.
Gatto M; Saccon F; Zen M; Regola F; Fredi M; Andreoli L; Tincani A; Urban ML; Emmi G; Ceccarelli F; Conti F; Bortoluzzi A; Govoni M; Tani C; Mosca M; Ubiali T; Gerosa M; Bozzolo E; Canti V; Cardinaletti P; Gabrielli A; Tanti G; Gremese E; De Marchi G; De Vita S; Fasano S; Ciccia F; Pazzola G; Salvarani C; Negrini S; Puppo F; Di Matteo A; De Angelis R; Orsolini G; Rossini M; Faggioli P; Laria A; Piga M; Mathieu A; Scarpato S; Rossi FW; de Paulis A; Brunetta E; Ceribelli A; Selmi C; Prete M; Racanelli V; Vacca A; Bartoloni E; Gerli R; Larosa M; Iaccarino L; Doria A
Arthritis Rheumatol; 2020 Aug; 72(8):1314-1324. PubMed ID: 32275125
[TBL] [Abstract][Full Text] [Related]
20. Flares in Chinese systemic lupus erythematosus patients: a 6-year follow-up study.
Peng L; Wang Z; Li M; Wang Y; Xu D; Wang Q; Zhang S; Zhao J; Tian X; Zeng X
Clin Rheumatol; 2017 Dec; 36(12):2727-2732. PubMed ID: 28929239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
